Telomir receives FDA clearance to begin human trials of lead cancer drug Telomir-Zn

Filed April 30, 2026 · Period ending April 24, 2026 · ~1 min read

Key Changes

• high

  FDA cleared IND application for Telomir-Zn in advanced triple-negative breast cancer, enabling first human trials of the company's lead drug candidate

  Item 8.01 verify on EDGAR →
• high

  Phase 1/2 trial to enroll ~76 patients starting first half 2026, with Phase 1 establishing safe dosing and Phase 2 measuring tumor response rates

  Item 8.01 verify on EDGAR →
• high

  Primary Phase 2 endpoint is objective response rate (ORR), with secondary measures including progression-free survival, overall survival, and duration of response

  Item 8.01 verify on EDGAR →